Drug intelligence / Profile preview

CF-602

Development stage: Preclinical
Lead developer: Can-Fite BioPharma
Administration: Topical, Oral

Overview

CF-602 is a nutraceutical candidate currently in the technology development (TechDev) stage, developed by Zhongke CELFULL Mitochondrial Medicine. The product is positioned within the company's mitochondrial medicine portfolio and is specifically aimed at addressing aging. As a nutraceutical, it is intended for health maintenance or the prevention of age-related decline, though its precise active ingredients and molecular targets remain proprietary and have not been detailed in public pipeline documentation.

Targets

ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on CF-602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF-602.

Explore the full profile